RxDoctor Payments Data

Zhiqi Feng

Family Medicine · Las Vegas, NVNPI 1093205510

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,396 of the $11,601 with a category attached, or 81.0%. It is spread thinly across 43 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$11,601in general payments, 2019–2025

Across 353 payments — averaging $32.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Gilead$1K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Scynexis, Inc.$1K
  • Novo Nordisk$846
  • Bayer$821
  • plus $5K from 37 others

What the payments were for

  • Consulting fees$2,20019%
  • Food & beverage$9,39681%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,601 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol137$125,450
JardianceEmpagliflozin111$105,032
EliquisApixaban122$54,560
VascepaIcosapent Ethyl82$53,167
JanuviaSitagliptin Phosphate30$45,239
ProliaDenosumab20$34,168
OzempicSemaglutide23$28,221
XareltoRivaroxaban39$24,858
VemlidyTenofovir Alafenamide16$22,627
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$21,265
MyrbetriqMirabegron47$18,402
Diclofenac Epolamine27$17,187
TradjentaLinagliptin16$16,525
LinzessLinaclotide25$16,478
DapagliflozinDapagliflozin Propanediol26$11,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,571$146,715162 claims
Boehringer IngelheimJardiance, Tradjenta$519$121,557127 claims
PfizerEliquis$169$54,560122 claims
MerckJanuvia$16$45,23930 claims
AmgenProlia, Corlanor$618$38,66137 claims
Novo NordiskOzempic$846$28,22123 claims
GileadVemlidy$1,360$22,62716 claims
Astellas Pharma US IncMyrbetriq$125$18,40247 claims
AbbVieLinzess$212$16,47825 claims
GSKBreo Ellipta, Anoro Ellipta$226$15,87030 claims
NovartisEntresto$95$11,01123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →